Ivonescimab
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pleural Mesotheliomas
Conditions
Pleural Mesotheliomas
Trial Timeline
Jun 30, 2025 → Mar 31, 2028
NCT ID
NCT06840834About Ivonescimab
Ivonescimab is a phase 2 stage product being developed by Summit Therapeutics for Pleural Mesotheliomas. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06840834. Target conditions include Pleural Mesotheliomas.
What happened to similar drugs?
0 of 4 similar drugs in Pleural Mesotheliomas were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07234877 | Phase 2 | Recruiting |
| NCT07094685 | Phase 2 | Recruiting |
| NCT06959550 | Phase 2 | Recruiting |
| NCT06980077 | Phase 2 | Recruiting |
| NCT06940518 | Phase 2 | Recruiting |
| NCT06840834 | Phase 2 | Recruiting |
| NCT06925724 | Phase 2 | Recruiting |
| NCT06805617 | Phase 2 | Recruiting |
| NCT06672575 | Phase 1/2 | Recruiting |
| NCT06567314 | Phase 2 | Recruiting |
Competing Products
20 competing products in Pleural Mesotheliomas